Jan 9 (Reuters) - Moderna Inc is considering pricing its COVID-19 shot at $110 to $130 per dose in the United States when it shifts from government contracting to commercial distribution of the shots, the company's Chief Executive Officer Stephane Bancel told the Wall Street Journal on Monday. (Reporting by Raghav Mahobe in Bengaluru; Editing by Krishna Chandra Eluri)
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
123.1 USD | +1.32% | +6.23% | +23.98% |
15/07 | Moderna Insider Sold Shares Worth $1,756,177, According to a Recent SEC Filing | MT |
12/07 | China approves CSPC Pharma's RSV vaccine for clinical trials | RE |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+23.98% | 46.56B | |
+45.04% | 41.67B | |
-1.73% | 41.16B | |
+34.62% | 32.4B | |
+20.76% | 28.18B | |
-6.35% | 28.1B | |
+49.54% | 14.52B | |
+46.80% | 13.74B | |
+0.40% | 12.17B | |
-8.09% | 11.14B |
- Stock Market
- Equities
- MRNA Stock
- News Moderna, Inc.
- Moderna considers pricing COVID vaccine at $110-$130 - WSJ